Treatment of Fungal and Inflammatory Conditions

Mechanism of Action and Clinical Applications

The American Academy of Dermatology recommends triamcinolone, a synthetic corticosteroid, for reducing inflammation in conditions such as acne nodules, allergic rhinitis, and various dermatologic conditions, with a mechanism of action that suppresses inflammatory responses 1, 2
The American Academy of Dermatology suggests that triamcinolone has no antifungal properties, whereas nystatin, a topical antifungal agent, works by decreasing the burden of Candida through direct contact with yeast cells, with minimal systemic absorption, making it safe for topical use 1, 3, 4, 5
Nystatin is specifically used to treat fungal infections, including oral candidiasis, vaginal candidiasis, and cutaneous candidiasis, with clinical cure rates of 32-51% for oral candidiasis in pediatric populations, and 42.8-48.5% for cutaneous candidiasis 3, 4, 5, 6, 7, 8

The American College of Physicians recommends triamcinolone for acute gout, with comparable efficacy to NSAIDs, though requiring fewer reinjections than corticotropin, and effective for allergic rhinitis symptom control, with a strength of evidence rated as high 1, 2, 9, 10
The Infectious Diseases Society of America notes that nystatin has a minimal systemic absorption, resulting in an excellent safety profile, with potential concerns for necrotizing enterocolitis in premature infants when used orally, and generally well-tolerated with few side effects 3, 4, 5, 11

The Centers for Disease Control and Prevention recommend switching to oral fluconazole 3-6 mg/kg once daily for 7-14 days as first-line alternative for nystatin-resistant oral thrush, achieving 91-100% clinical cure rates, and applying topical miconazole 2% cream or clotrimazole 1% cream once daily for 7-14 days for nystatin-resistant cutaneous candidiasis, with cure rates of 80-90% 6, 7, 8

The CDC MMWR recommendations endorse nystatin for oral candidiasis (400,000–600,000 units four times daily for adults), vaginal candidiasis (100,000‑unit tablets once daily for 14 days), and cutaneous candidiasis, noting that these regimens are not associated with systemic side effects. 12, 13

In patients receiving oral nystatin suspension, coagulation monitoring (e.g., INR) remains unchanged even in those on warfarin therapy, confirming that nystatin exhibits minimal systemic absorption and does not produce systemic laboratory abnormalities. 14

Unlike systemic azole antifungals (e.g., fluconazole, voriconazole, itraconazole) that can cause systemic and ocular adverse effects through systemic absorption and CYP450 interactions, nystatin remains localized to the site of application and therefore does not produce ocular toxicity. 14